8th Annual Forum Pathways To Access & Reimbursement 2023 | The Canadian Institute | 19 January 2023 | DoubleTree by Hilton Hotel Toronto Downtown, 108 Chestnut St, Toronto, ON M5G 1R3, Canada

Offering a critical analysis of Canada’s access and reimbursement environment, and in-depth discussions on how to adapt market access strategies especially at a time when affordability and overall health system sustainability are top of mind.

This annual forum will host critical conversations, examining the most vexing questions and challenges hovering over manufacturers, payers, and patient groups alike, while also exploring opportunities to empower decision-making so that the right treatment reaches patients at the right time.

Who Attends?
Practitioners at every level with experience in:
• Pricing
• Reimbursement
• Market access
• Patient access
• Government and regulatory affairs
• Health economics
• Research and development
• Policy and compliance
• Pharmacy services
• Marketing
• National trade
• Formularies
• Business development
• Sales
From brand generic and manufacturing companies involved in:
• Product development
• Public drug programs
• Pharmaceutical benefits
• Pharmaceutical strategy
• Drug submissions
• Formulary management
• Policy and economic analysis
• Provider services and relations
• Pharmacy

2022 Speakers

CONFERENCE CHAIRS:

Farah Jivraj
Head - Market Access and Stakeholder Relations, Biogen

Dipti Tankala
Manager - Market Access & HEOR, AbbVie

SPEAKERS:

Erin E. Atkins
Senior Attorney, ArentFox Schiff LLP

Jaclyn Beca
Director - Pharmacoeconomics and RWE, Morse Consulting

Onil Bhattacharyya
Senior Scientist, Women's College Research Institute

Louise Binder
Health Policy Consultant, Save Your Skin Foundation

Sylvie Bouchard
Director - Drug Evaluation and Technology Assessment for Reimbursement, INESSS

Kiersten Combs
Country President - Canada, AstraZeneca

Priti Chawla
Founder & Executive Director, Obesity Matters

Rosemarie Childerhose
Director - Market Access & Government Affairs, Bausch Health

Sandra Elia
Board Chair - Director of Education & Patient Advocacy, Obesity Matters

Karen Facey
Health Policy Consultant, RWE4Decisions

Susan Fitzpatrick
Head, Canadian Drug Agency Transition Office

Harriet E Feilotter
Professor - Department of Pathology and Molecular Medicine, Queen's University Cancer Research Institute

Mark Harrison
Associate Professor, University of British Columbia

Don Husereau
Adjunct Professor of Medicine, University of Ottawa

Craig Ivany
Chief Provincial Diagnostics Officer, Provincial Health Services Authority

Paul Kryzanowski
Medical Director - Precision Medicine, The Janssen Pharmaceutical Companies of Johnson & Johnson

Fred Little
Country Lead Rare Disease, Pfizer

Andrea Masters
Director - Strategic Access and Pricing Lead, Roche

Suzanne McGurn
President and CEO, CADTH

Dr. Nicole Mittmann
Chief Scientist and Vice-President Evidence Standards, CADTH

Dr. Danielle Paes
Chief Pharmacist Officer (CPO), Canadian Pharmacists Association

Dr. Daria O’Reilly
Lead Health Economist / Pharmacy Consulting / Health Benefits Management, TELUS Health

Tanya Potashnik
Director - Policy and Economic Analysis, Patented Medicine Prices Review Board

Mina Tadrous
Assistant Professor, University of Toronto

Dominic Tan
Senior Manager, pan-Canadian Pharmaceutical Alliance

Durhane Wong-Rieger
President, CORD

Dr. Sean Wharton
Medical Doctor, Wharton Medical Clinic

Nicole Yada
Manager, ICES

2023 Partner

MEDIA PARTNER:
• Innovative Medicines Canada